Back to top

Cytokinetics reports ACACIA-HCM trial met both primary endpoints

Cytokinetics (CYTK) announced the primary results from ACACIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic non-obstruc...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cytokinetics, Incorporated (CYTK)